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Abstract
A great number of scientific studies have shown that the development of different TNBC 
forms is closely associated with the induction of various signaling pathways and that TNBC 
cells show greater sensitivity to different drugs. Recent studies showed hypoxia-inducible 
factor-1α (HIF-1α) was strongly correlated to clinicopathological features in many types 
of cancers. This molecule seems to play a significant role in the development of different 
tumors and breast cancer among them. The aim of this study was to evaluate the relation-
ship between immunohistochemical expression of novel prognostic marker—HIF-1α—and 
clinicopathological features for patients with triple-negative breast cancer. Among 162 
breast cancer patients, we identified 111 (68.5%) subjects with triple-negative breast cancer. 
In our study, TNBC was most commonly assessed as G2 and G3 (52.2%; 45.1%), pT1 and pT2 
(34.2%; 62.1%), and pN1 and pN2 (45%; 41.4%). TNBC more often presented HIF-1α expres-
sion (43.2%) than non-TNBC (35.2%). TNBC subgroup demonstrated significant correla-
tion between HIF-1α expression and tumor size (pT1–pT4) (p = 0.021), which may suggest 
that HIF-1 alpha expression in this group of patients may be an additional and significant 
marker in the evaluation of the advance of the disease, affecting therapeutic decisions.
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1. Introduction
Breast cancer is the most common cancer in women [1], and it comprises heterogeneous tumors 
with different biological features, clinical course, prognosis, and response to treatment [2]. 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
With modern techniques, we can distinguish many molecular forms of breast cancer [3], which 
is important because the molecular classification of breast cancer enables effective, individual-
ized treatment [4]. Based on cDNA microarray and immunohistochemical analysis, five basic 
molecular subtypes of breast cancer have been distinguished:
• luminal subtype A (ER+ and/or PR+, HER2−, CK5/6−)
• luminal subtype B (ER+ and/or PR+, HER2+, CK5/6−)
• basal-like subtype (ER−, PR−, HER2−, CK5/6+)
• subtype with overexpression of the HER2 gene (ER−, PR−, HER2+, CK5/6−)
• subtype with expression of genes typical for cells of the normal mammary gland (normal 
breast-like)
• subtype with a decreased expression of genes coding proteins responsible for intercellular 
junctions and adhesion of epithelial cells (claudin and cadherin E) [5, 6]
On routine histology, breast cancer is defined based on immunohistochemical detection of 
three receptor proteins: estrogen receptor (ER), progesterone receptor (PR), and HER2 recep-
tor with additional gene status analysis of the HER2 gene (in situ hybridization). This immu-
nohistochemical profiling shows that 25% of breast cancers consist of type A luminal cells; 
32%, of type B/HER2− cells; 18.5%, of luminal B/HER+ cells; and 7%, of cells that express 
solely the HER2 protein [7]. Cancers of the luminal subtype A and B express genes character-
istic for glandular cells, which form the inner layer of normal ducts and lobules of the breast. 
Moreover, the luminal subtypes of breast cancer express cytokeratins typical for glandular 
cells, such as cytokeratins 8, 18, and 19, as well as α 6 integrins and Bcl-2, Ep-CAM, and MUC1 
proteins. The luminal subtype A is characterized by a high expression of genes for estrogen 
receptors and progesterone receptors and genes regulating the function of these receptors, 
i.e., FOX1, GATA3, LIV-1, and XBP1. The luminal subtype A breast cancer typically occurs in 
young patients; in contrast to the luminal subtype B, the luminal subtype A breast cancer has 
a good prognosis [8–10]. In recent years, among all the molecular subtypes of breast cancer, 
the triple-negative breast cancer (TNBC) has been studied most extensively.
2. Characterization of the triple-negative breast cancer
The TNBC is a subtype of breast cancer that lacks steroid receptors, i.e., estrogen and proges-
terone receptors, and does not overexpress the HER2 gene. Eighty percent of patients with the 
TNBC have the basal type of breast cancer, according to the molecular classification [1, 3, 8]. 
About 15–20% of all patients with breast cancer have the TNBC, which is more common in 
patients younger than 50 years. The risk factors for the TNBC are as follows:
• young age at menarche
• obesity in the menopausal age
• family history of breast cancer
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The TNBC has an aggressive course, grows fast, and metastasizes early, usually to the brain 
and lungs, and less commonly to the bones and liver. Compared with other breast cancers, 
the TNBC is poorly differentiated (G3) in the Bloom-Richardson classification [5, 6, 9]. In 2010, 
studies among 15,240 women with breast cancer, including 2500 with the TNBC, showed that 
patients with the TNBC had a worse prognosis than other patients [5, 6, 8–10].
The TNBC is also characterized by early recurrence, usually within 1–3 years after diagno-
sis [8]. Most patients with TNBCs have a poor prognosis because adjuvant therapy rarely 
leads to remission, and the presence of metastases is associated with a high resistance to 
chemotherapy and short survival [9]. Not all patients with TNBC, however, have a poor 
prognosis [6, 7, 9]. Numerous studies showed that the TNBC is related to the dysfunction of 
the BRCA genes and their protein products [9, 10]. According to Atchley et al. [10], TNBCs 
occur in 57% of patients with breast cancer and BRCA1 mutations. Moreover, more than 
a half of TNBCs overexpress the MGFR receptor (c-Met growth factor receptor), which is 
associated with the signaling pathway initiating the epithelial-mesenchymal transforma-
tion [8, 9]. The TNBC is often associated with P53 mutations, PTEN loss, activation of the 
PI3K/AKT signaling pathway, and loss of heterozygosity of the loci4p14, 4p15.3 m 5q11.1, 
5q14, and 18q22–23 [11].
Although TNBC was initially detected in basal-like carcinoma, these two types of breast can-
cer are different from each other [12]. The basal-like carcinoma is diagnosed based on the 
immunohistochemical status of steroid receptors (ER, PR) and the HER2 receptor [4, 7, 9].
Molecularly, the TNBC comprises a heterogeneous group of tumors. Lehmann et al. [13] dis-
tinguished six types of the TNBC:
• basal-like 1 and basal-like 2 (BL1 and BL2)
• immunomodulatory (IM)
• mesenchymal (M)
• mesenchymal stem-like (MSL)
• luminal androgen receptor (LAR)
• unstable
Of all these TNBC subtypes, only the LAR TNBC does not express basal cytokeratins, such 
as CK5, CK6A, CK6B, CK14, CK16, CK17, CK23, and CK81, and it does not express proteins 
such as EGFR, p53, smooth muscle actin, P-cadherin, and c-Kit receptor [10, 11]. In contrast, 
the LAR TNBC expresses CK7, CK8, CK18, CK19, and the androgen receptor [12]. Moreover, 
the LAR TNBC expresses genes whose protein products regulate hormonal pathways and the 
gene for the androgen receptor and its co-activators [12, 13].
The BL1 TNBC expresses genes whose protein products are associated with cell cycle regula-
tion, cell proliferation, repair process, and DNA replication [12].
The BL2 TNBC expresses genes whose protein products are involved in the signal transduction 
in the cell, through growth factors such as EGF, NGF, MET, Wnt/β-catenin, and IGF1R [12].
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The IM TNBC is characterized by the expression of genes whose protein products are involved 
in immune reactions, such as signal transduction in Th1 and Th2 cells, natural killer cells, and 
dendritic cells [10, 12].
The M TNBC is characterized by the expression of genes whose protein products regulate cell 
mobility, interaction of cells with the extracellular matrix, and cell differentiation and growth [12].
The MSL TNBC expresses genes whose protein products are involved in angiogenesis and the 
signaling pathways of the ABC transporters [12, 13].
Most subtypes of the TNBC have the molecular profile typical for the basilar subtype of breast 
cancer, which lacks expression of ER, PR, and HER2 [8, 9, 12]. This molecular profile is observed 
mainly in subtypes BL1 (85%) and BL2 (31%), and subtypes IM (58%) and M (47%) [8, 12].
Usually, the LAR TNBC is a luminal A or B breast cancer (82%) [12–14]. Based on immuno-
histochemical studies, 50–80% of TNBCs are basal-like cancers, and conversely, 77–80% of 
basal-like breast cancers are TNBCs [9, 10, 12]. Molecular analyses indicate that TNBCs and 
the basal subtype of breast cancer are different cancers [13–15].
All the above-mentioned subtypes of the TNBC incur different prognoses; the longest recur-
rence-free survival is found in patients with the MSL TNBC, and the shortest recurrence-free 
survival, in patients with the LAR TNBC [15].
Histologically, the majority of TNBCs are luminal cancers (invasive carcinoma of no special 
type—IDC—NST) [15]. The TNBC occurs more commonly in patients with specific histological 
types of breast cancer, including the medullary breast cancer, metaplastic breast cancer, apo-
crine breast cancer, salivary gland-like breast cancer, secretory breast carcinoma, breast cancer 
derived from lipid-laded cells, and lobular breast carcinoma [16]. In patients with TNBCs, it is 
the histological type of the tumor that determines its biological properties; thus, patients with 
TNBCs do not always have rapid disease progression and poor prognosis [17, 18].
To identify a homogenous group of patients, Eiermann et al. [19] suggested that the tumors 
that become triple-negative after neoadjuvant treatment, and were not triple-negative before 
this treatment, should not be classified as TNBC. However, if the disease recurs as triple-
negative metastases, the tumor should be considered as triple-negative although the primary 
tumor was not triple-negative [19]. According to these investigators, also rare histological 
subtypes of the TNBC, such as apocrine, glandular, or low-differentiated cancers, should be 
excluded from the group of triple-negative cancers [18, 20].
3. Treatment of patients with TNBC
Patients with the TNBC do not benefit from hormonal treatment or treatment with anti-HER2 
antibodies (trastuzumab) because their tumors do not express the ER, PR, and HER2 receptors. 
Therefore, surgery, radiation therapy, and chemotherapy, used alone or in various combina-
tions, are currently the only reliable therapeutic options for patients with TNBCs. However, 
recent research on TNBC has identified many receptors that could be used as future therapeutic 
Breast Cancer and Surgery82
targets. Until this is achieved, chemotherapy remains the mainstay of systemic treatment for 
patients with stage I to stage III TNBC. Currently, none of the standard chemotherapy regimens 
is considered superior for patients with TNBCs, and treatment of these patients is based on the 
same principles as that in patients with other subtypes of breast cancer. Most guidelines recom-
mend a regimen based on the combination of an anthracycline with a taxane.
The therapeutic strategies for the management of TNBC are targeting the DNA repair com-
plex (platinum compounds and taxanes), P53 (taxanes), and cell proliferation (anthracy-
cline-containing regimens) [21]. Despite the aggressive clinical course, the TNBC’s response 
to chemotherapy is good. However, despite achieving high rates of pathological complete 
response (pCR) with conventional chemotherapy, the TNBC phenotype is associated with 
higher recurrence rates than the ER+ and HER2+ breast cancers. This is known as the triple-
negative paradox [22].
Since the first application of taxanes, used in adjuvant therapy for over 20 years, relatively 
few new treatments have appeared in recent years for patients with the TNBC. New thera-
peutic methods are still lacking despite numerous ongoing clinical trials. Many retrospec-
tive studies have demonstrated that tumor infiltrating lymphocytes (TILs) are of prognostic 
importance in patients with early-stage TNBC. Increased TIL numbers within the neoplastic 
milieu correlate with a better response to the standard treatment regimen with anthracyclines 
in neoadjuvant therapy [23].
However, it has still not been shown whether the presence of TILs identifies tumors that are 
more susceptible to treatment, or whether the presence of lymphocytes itself increases the 
effectiveness of treatment [23]. There are numerous reports on the benefits of using plati-
num derivatives in chemotherapy, in particular in cancers with the BRCA1 mutation, which 
is much more frequent in TNBCs (about 30%) than in other cancers. Nearly 80% of tumors 
that develop in carriers of the BRCA1 mutation are triple-negative. The BRCA mutation status 
is increasingly therapeutically relevant beyond consideration of prophylactic mastectomy/
oophorectomy and surveillance. A recent randomized phase III trial demonstrated that in 
unselected patients with the metastatic TNBC, carboplatin and docetaxel were equal in effi-
cacy as first-line treatments [24].
However, in the BRCA mutation-associated TNBC, carboplatin yielded a superior response 
rate and progression-free survival compared with docetaxel. The improvement in pCR 
attained with the addition of carboplatin to anthracycline/taxane chemotherapy comes at the 
cost of increased toxicity. Because of the molecular variability of TNBCs, the platinum deriva-
tives improve prognosis only in some patients. Therefore, it is very important to identify those 
patients with TNBC who will have the greatest benefit [25]. The current highest pCR rates, 
about 40–45%, are achieved by taxane/anthracycline sequential chemotherapy regimens and 
inclusion of platinum drugs with the taxane component. Inclusion or substitution of other 
chemotherapy drugs (capecitabine, gemcitabine, vinorelbine, or ixabepilone) resulted in little 
or no improvement in pCR rates [26, 27]. To date, all clinical trials showed that the neoadju-
vant chemotherapy was the preferred option for patients with TNBC who required systemic 
therapy. Neoadjuvant chemotherapy studies have consistently reported higher response 
rates in TNBC than in non-TNBC, and pCR has been shown to predict improved long-term 
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outcomes for patients with TNBC. The specific adjuvant regimens that may be effective for 
TNBC are still being determined. Many large randomized trials have established the benefit 
of adjuvant anthracyclines and taxanes in breast cancer [28].
The evidence consistently shows that 10–20% of patients with TNBC who would not experi-
ence pCR following treatment with a current third-generation taxane and anthracycline will 
achieve pCR when a platinum drug is added to the regimen. However, because of the substan-
tial added toxicity and predicted modest overall survival benefit across patient subgroups, car-
boplatin and cisplatin have not been routinely incorporated into neoadjuvant treatment [29].
The principles of local treatment in breast cancer, i.e., surgery and radiotherapy, are the same 
for the TNBC and all other types of breast cancer. Over the last several years, the percentage 
of patients operated on for breast cancer has increased; this trend has also been observed in 
patients with TNBC.
In patients with the TNBC, radiation therapy is given as in other types of breast cancer, i.e., 
after mastectomy or breast-conserving surgery. However, this approach to radiation therapy 
remains controversial because more and more patients have TNBCs, which has a fast local 
growth. The general rule that breast-conserving surgery followed by radiation therapy in 
early stage cancers (T1-2 N0) is the equivalent of mastectomy, in this case, has many limita-tions. Also the general consensus that post-mastectomy radiation therapy is not indicated for 
patients with node-negative tumors less than 5 cm in diameter should not be oversimplified 
in patients with triple-negative tumors [28].
4. Targeted therapy in TNBC
Although chemotherapy can be effective in patients with TNBCs, molecular studies could still 
improve treatment outcomes by giving new treatment targets. The molecular heterogeneity 
of TNBCs means that patients with TNBCs need personalized treatment because currently 
60–70% of patients with TNBC do not respond fully to chemotherapy. Genomic analyses of 
the TNBC revealed large-scale transcriptional, mutational, and copy number heterogeneity, 
without any frequently recurrent mutations, other than TP53. Consistent with this molecular 
heterogeneity, most targeted agents, so far, have a very low activity in unselected TNBC, but 
important “basket” trials are ongoing. Therefore, there are promising opportunities for study-
ing targeted therapy in appropriately selected patients with residual disease after neoadjuvant 
chemotherapy. Several ongoing phase I/II studies are investigating phosphatidylinositol-3-ki-
nase (PI3K) inhibitors in advanced TNBC, and early-phase studies are also assessing Janus 
kinase 2 and cyclin-dependent kinase inhibitors in hormone-negative breast cancer [29].
At least some important discoveries made in recent years seem to be worth emphasizing in 
this textbook. The molecular pathways and receptors mentioned below might become new 
treatment targets for patients with the TNBC.
4.1. Anti-angiogenic factors
Blockage of angiogenesis has been one of the ways to treat patients with breast cancer. In 
patients with the TNBC, bevacizumab, among the drugs that interfere with angiogenesis, has 
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been studied most extensively. In 2008, the Food and Drug Administration (FDA) approved 
bevacizumab in combination with a taxane (paclitaxel) as first-line therapy for metastatic 
HER2-negative breast cancer, including the TNBC [30]. A meta-analysis of phase III studies 
with bevacizumab showed an improvement in progression-free survival but not in overall 
survival in these patients. However, the addition of bevacizumab considerably increased 
treatment toxicity [31].
Based on these data, in 2011, the FDA withdrew bevacizumab as the treatment for metastatic 
breast cancer.
4.2. Immune checkpoint inhibitors
Because we know more and more about the interaction of inflammatory cells with cancer cells, 
in future, immunotherapy might be introduced for the treatment of breast cancer. Cancer cells 
use many mechanisms to avoid immune responses. For instance, in the TNBC, cancer cells 
express the PD-1 antigen and its ligands on cell surface. These proteins induce T lymphocyte 
tolerance. Preclinical studies showed that blocking the activity of the PD-1/PD-L1 might be 
used as treatment for TNBC. Both anti PD-1 antibodies (pembrolizumab and nivolumab) and 
an anti-PD-L1 antibody (atezolizumab) showed promise in preclinical studies [32].
4.3. PARPi
Poly-ADP-ribose polymerases (PARPs) are enzymes that are essential for cell survival. Cell 
damage activates PARPs, which, in turn, induces cell repair systems that maintain genome 
stability and regulation of transcription. Preclinical studies showed that PARPs are inhibited 
in cancer cells with pre-existing DNA repair defects, e.g. with the BRCA1 mutations. The 
FDA has recently approved monotherapy with olaparib, a PARPi, as a first-in-class drug to 
treat germline BRCA mutation-associated advanced refractory breast cancer. Several ongoing 
studies are assessing the activity of PARPi alone or in combination with chemotherapy for 
germline BRCA-associated metastatic and early-stage breast cancers. Because a substantial 
proportion of TNBCs are thought to harbor DNA repair defects, it might be possible to extend 
the observation of PARPi sensitivity of germline BRCA-associated tumors to BRCA wild-type 
TNBCs that harbor a BRCAness phenotype. Accordingly, PARPi are being explored in the 
general population of patients with the TNBC [33].
4.4. PI3K/AKT/mTOR pathway inhibitors
The high frequency (about 50%) of PI3K pathway alterations in the TNBC makes this pathway 
a promising target for therapeutics, and inhibitors of PI3K, AKT, and/or mTOR are in clinical 
development. PI3K blockade promotes HR deficiency by downregulating BRCA1/2 and thus 
sensitizing BRCA-proficient tumors to PARP inhibition [34].
4.5. Histone deacetylase inhibitors
These drugs modulate gene expression through epigenetic regulation and can induce cell 
cycle arrest, differentiation, and apoptosis. Panobinostat is a potent pan-histone deacetylase 
inhibitor with preclinical activity in the TNBC. Several histone deacetylase inhibitors are 
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currently being tested as treatment for metastatic TNBC in combination with chemotherapy 
or with immune checkpoint inhibitors [35].
4.6. Androgen-targeted therapy
TNBCs expressing the androgen receptor (AR-positive) account for about 10% of all TNBCs 
and are characterized by a more benign course [13]. These tumors express the AR, which can 
be detected by immunohistochemistry or the analysis of AR gene expression. AR-positive 
TNBCs have several common features with ER-positive breast tumors, including the expres-
sion of several estrogen-dependent genes and the frequent presence of PIK3CA mutations. 
Anti-androgens have been studied as potential drugs for these cancers. Few TNBCs express 
AR, and patients with AR-positive tumors were qualified for clinical trials with anti-androgens. 
Many molecules have been studied, but data on bicalutamide and enzalutamide are most exten-
sive. Unfortunately, few patients responded to the treatment with these agents. Nonetheless, 
20–35% of patients achieved disease stabilization [36]. It remains unclear whether these find-
ings reflect the relatively mild nature of AR-positive TNBCs or whether they reflect the actual, 
but limited, activity of anti-androgens.
4.7. Other agents
New treatment targets for patients with cancer are being studied. These include, among oth-
ers, reparixin (inhibitor of interleukin-8 activation of CXCR1/CXCR2 chemokine receptors), 
CXCR1/2 (stem cell pathway), cyclin-dependent kinases, c-Met pathway, aurora kinase inhib-
itor, death receptors, and CSF1 inhibitor (colony stimulating factor 1).
After over 20 years with relatively few new treatments for the TNBC, recent years have 
seen a growing interest in the TNBC among researchers. This is because more and more 
people with breast cancer have the TNBC, which is aggressive and tends to metastasize. 
Currently, studies are assessing different chemotherapy regimens and are testing the use-
fulness of new targeted therapies. In the early stages of the TNBC, standard neoadju-
vant chemotherapy might save patients’ lives; patients who receive standard neoadjuvant 
therapy can later receive adjuvant chemotherapy or be included in clinical trials if there 
is extensive residual cancer after neoadjuvant therapy. Growing evidence supports the 
benefit of adding cisplatin to the chemotherapy with taxanes/anthracyclines in patients 
with BRCA mutations [37].
Because many new targeted therapies for the TNBC are assessed in ongoing trials, we hope 
that the treatment of TNBC will soon be improved.
5. Hypoxia in TNBC
A great number of scientific studies have shown that the development of different TNBC 
forms is closely associated with the induction of various signaling pathways and that TNBC 
cells show greater sensitivity to different drugs. Recent studies showed hypoxia-inducible 
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factor-1α (HIF-1α) was strongly correlated to clinicopathological features in many types of 
cancers. This molecule seems to play a significant role in the development of different tumors 
and breast cancer among them.
HIF-1α is responsible mainly for cellular adaptation to hypoxic conditions; therefore, genes 
triggered by this factor are responsible mainly for the improvement in oxygen supply (by 
increasing angiogenesis, broadening the lumen of existing vessels, increased erythropoiesis 
or increased iron consumption), adaptation of cells to anaerobic metabolism conditions as 
well as for other changes facilitating cell survival in insufficient oxygen availability and modi-
fying the main metabolic pattern. Stimulation of angiogenesis promotes the increased risk 
of distant metastases. Better accessibility of blood vessels increases the chance of tumor cells 
finding their way into the bloodstream and being transported to niches allowing settlement 
and formation of a metastatic lesion [38].
Hypoxia-inducible factor 1 is a master transcriptional regulator of genes regulating oxygen 
homeostasis. The HIF-1 protein is composed of two HIF-1α and HIF-1β/aryl hydrocarbon 
receptor nuclear translocator subunits. The prognostic relevance of HIF-1α protein overex-
pression has been shown in breast cancer. The impact of HIF-1α alternative splice variant 
expression on breast cancer prognosis in terms of metastasis risk is not well known.
Therefore, Dales et al. [39] investigated the prognostic value of different HIF-1α transcript 
expression levels in breast cancer and found a significant relationship between either clinico-
pathological characteristics or patient metastasis-free survival. They proved mRNA expres-
sion of a HIF-1αTAGsplice variant reflects a stage of breast cancer progression and is associated 
with a worse prognosis [39].
Due to the fact that TNBC frequently shows morphologic evidence of hypoxia (central fibrosis 
and necrosis) [40, 41] an augmented expression of HIF-1α in tumors with a triple-negative 
phenotype should be anticipated. In fact, this had been elegantly demonstrated through the 
preferential expression of HIF-1α in peri-necrotic tumor cells in TNBC and BRCA1 mutated 
breast cancers [42].
In contrast, Tan et al. [43] and Choi et al. [44] demonstrated in TNBC an increase of car-
bonic anhydrase IX, a downstream product of the hypoxic pathway, rather than an increase 
in HIF-1α per se. The authors did not dispute the likely contribution of hypoxia to the tumors’ 
aggressive phenotype.
HIF-1α overexpression is an indicator of poor prognosis and significant survival time reduc-
tion in patients suffering from breast cancer [45]. HIF-1 upregulates transcription of angio-
genic genes like erythropoietin (EPO) and vascular endothelial growth factor (VEGF), which 
induce sprouting of new vessels and in result they increase the risk of metastasis because they 
boost surface of contact between tumor cells and vasculature. HIF-1 induces transcription of 
cytoprotective proteins in malignant cells in hypoxic conditions. HIF-1α predicts poor prog-
nosis breast cancer [46, 47].
The relationship between inflammation and tumor progression is widely accepted. This phe-
nomenon is also well known in breast cancer, and is mediated by numerous interleukins. 
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Besides playing a central role in the induction of inflammatory processes, interleukin 1β (IL-
1β) was also identified as a factor important for progression of the tumor and stimulation of 
angiogenesis as well as being responsible for the increase in the invasiveness of cancer lesions. 
Recently, there has been considerable interest in understanding the non-hypoxic upregulation 
of the hypoxia-inducible factor HIF-1α by IL-1 in neoplastic cells since aberrant expression of 
HIF-1α correlates with tumor progression. Naldini et al. [48] studied the effect of IL-1β on cell 
migration and HIF-1α accumulation in the human invasive breast cancer cell line MDA-MB-231.
It was found that hypoxia-independent induction of HIF-1α by IL-1β was associated with an 
increase in cell migration and a simultaneous increase in the activity of phosphorylated p38 
MAPK and CXCR1 expression. Inhibition of HIF-1α by siRNA led to a significant reduction in 
CXCR1 expression and cell migration, confirming the role of HIF-1α in hypoxia-independent, 
IL-1β-induced migration of the MDA-MB-231 line cells. The results of the studies present a 
new role of IL-1 in breast cancer. The therapeutic approach focused on inhibition of IL-1β 
activity appears to be a new target for the research aimed at the development of novel meth-
ods to treat invasive breast cancer [48].
6. Aim
The first aim of our study was to evaluate the expression of ER, PR and HER2 in order to extract 
a group of TNBC and non-TNBC. The second aim of this study was to evaluate the relation-
ship between immunohistochemical expression of novel prognostic marker—HIF-1α—and 
clinicopathological features for patients with triple-negative breast cancer.
7. Materials and methods
Studies were conducted in a group of 162 patients with breast carcinoma with lymph node 
metastasis (111 triple-negative breast cancer and 51 non-triple-negative breast cancer) in the 
Department of Pathology, Military Medical Institute in Warsaw. Material for the study came 
from biopsies, excisional biopsies and modified radical mastectomies. Tumor samples were 
fixed in 10% buffered formalin phosphate. After 24-h fixation, material was dehydrated using 
alcohol in gradually increasing concentrations and embedded in paraffin. Paraffin blocks were 
cut into serial sections 4 μm in thickness. They were then stained using standard methods. The 
tumors were classified and graded according to the WHO and the Nottingham modification 
of the Scarff-Bloom-Richardson systems. In the sections stained with routine H&E method, 
the following determinations were carried out: type of neoplasm (WHO classification), tumor 
grade including tubule formation, and intensity of division as well as the degree of neoplastic 
cell differentiation and mitotic index as a mean number of mitotic figures in neoplastic cells 
counted in 10 fields of vision at a 400× magnification (surface field 0.17 mm2).
Paraffin sections on the slides covered with 2% saline solution in acetone at temperature of 
42°C were used for immunohistochemical examination.
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Routine tests were performed in order to determine immunohistochemical expression of 
basic profile of diagnostic markers, such as estrogen receptor (ER), progesterone receptor 
(PR) and HER2. Monoclonal antibodies against receptors for estrogen (Monoclonal Mouse 
Anti-Human Estrogen Receptor alpha, 1:50 dilution, Clone: 1D5, Code: IR654, DAKO) and 
progesterone (Monoclonal Mouse Anti-Human Progesteron Receptor, 1:400 dilution, Clone: 
PR636, Code: IR068, DAKO) were used in order to determine the expression of steroid recep-
tors. Evaluation of the immunohistochemical markers was performed by two pathologists 
as follows: ER and PR were categorized as negative—(0%), low positive—(1–10%); nuclear 
staining in >10% of tumor cells was considered positive for ER and PR.
The study was conducted as follows: sections were incubated at 60°C overnight and subse-
quently dewaxed. The next step involved revealing the epitope by heating the slides in a buffer 
for 40 min. Subsequently, preparations were left at room temperature for 20 min. Preparations 
were rinsed in buffer and endogenous peroxidase was blocked by washing in 3% H2O2 for 10 min. In the next step, preparations were incubated with an appropriate antibody for 30 min. 
After incubation, preparations were rinsed in buffer for 10 min, and then incubated with the 
reagent (Visualization Reagent) for 30 min. After incubation with the reagent, preparations were 
washed in TBS (Tris-Buffered Saline, Code: S1968) with pH 7.6 for 10 min, and then incubated 
with 3,3′-diaminobenidine (DAB) (Substrate—Chromogen Solution) for 10 min to visualize the 
color of the reaction. At the end of the procedure, preparations were stained with hematoxylin.
HER2 expression was determined using HerceptTest™ DAKO test (Code: K5204). It enabled 
detection of HER2 expression using a polyclonal antibody against this protein (Rb A—Hu 
HER2—Rabbit Anti-Human HER2 Protein). Antigen retrieval for HER2 using HerceptTest 
was performed by immersing and incubating the slides in 10-mmol/L citrate buffer in a cali-
brated water bath (95–99°C) for 40 min (±1 min). After decanting the epitope-retrieving solu-
tion, sections were rinsed in the wash buffer and later, soaked in the buffer for 5–20 min 
before staining. The slides were loaded onto the autostainer using the HercepTest program, 
as described in the manufacturer’s insert. In the autostainer, the slides were rinsed, placed 
in 200 μL of peroxidase-blocking reagent for 5 min, rinsed, placed in 200 μL of primary anti-
HER2 protein (or negative control reagent) for 30 min, rinsed twice and immersed in 200 μL of 
substrate chromogen solution – DAB for 10 min. The slides were counterstained with hema-
toxylin and finally coverslipped. HER2 results were determined based on the maximum area 
of staining intensity according to the instruction in the package insert and the ASCO/CAP 
guidelines as follows: strong, circumferential membranous, staining in >30% of invasive carci-
noma cell was scored 3+, moderate, circumferential, membranous staining in ≥10% of invasive 
tumor cells or 3+ staining in ≤30% of cells was designated as 2+ staining, weak and incomplete 
membranous staining in invasive tumor cells was scored 1+ and no staining was scored 0. 
Tumors with 0 and 1+ staining were considered negative.
A total of 162 cases of breast cancer with metastasis to lymph nodes were assessed for expres-
sion of HIF-1α (Monoclonal Mouse Anti-Human HIF-1α 1:50 dilution, Clone:28b, Santa Cruz 
Biotechnology®, Inc.). A visualization system ImmunoCruz™ Mouse ABC Staining System 
(Santa Cruz Biotechnology®, Inc.) was subsequently applied; tumor-cell immunoreactiv-
ity was scored according to both the extent of nuclear staining—relative number of HIF-1α 
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positive cells, and the intensity of the reaction: [−] not detected; [+] <1% positive cells; [+] 
1–10% weakly to moderately stained cells; [++] 1–10% intensively stained cells or 10–50% 
weakly stained cells; [+++] 10–50% positive cells with moderate to marked staining; [++++] 
>50% positive cells [49]. Positive controls were HIF-1α immunoreactive breast cancer tissues. 
Negative controls were prepared with omission of primary antibodies.
8. Statistical analysis
All statistical analyses were performed with SPSS software v12.0. The Chi-square (χ2) was used 
to assess the relationship between HIF-1α and degree of histological malignancy and clinical 
staging. The Fisher exact test was used when the expected cell counts were less than 5. The 
results were considered as statistically significant if the p value was less than 0.05 (p < 0.05).
9. Results
Histopathological examination was performed in tumors obtained from 162 patients suffer-
ing from breast cancer. Among 162 breast cancer patients we identified 111 (68.5%) subjects 
with triple-negative breast cancer (TNBC was identified as ER-negative, PR-negative, and 
HER2-negative) and 51 (31.5%) subjects with non-triple-negative breast cancer. Mean age of 
patients with TNBC was 47.8 and of patients with non-TNBC 60.4 years.
Histopathological subtyping of the 111 triple-negative breast cancers identified 89.1% inva-
sive ductal carcinomas of no special type (IDC-NST) (Figure 1) and 10.9% other special types 
of cancers: invasive lobular carcinomas, mixed ductal and lobular types, metaplastic carcino-
mas (Table 1).
All cases of triple-negative breast cancer were grouped according to histological grading: 3 
(2.7%) cases were grade 1 (G1), 58 (52.2%) cases were identified as grade 2 (G2) and 50 (45.1%) 
Figure 1. Triple negative breast cancer (TNBC) H&E.
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cases—grade 3 (G3). Given the histological grade of malignancy, G2 and G3 tumors com-
prised the largest group of triple-negative breast cancers.
In our study TNBC were most commonly assessed as G2 and G3 (52.2%; 45.1%), pT1 and pT2 
(34.2%; 62.1%), and pN1, pN2 (45%; 41.4%). Respectively non-TNBC were most commonly 
assessed as G2 and G3 (47%; 47%), pT1 and pT2 (39.2%; 47%) and pN1 (52.9%). In our study a sta-
tistically significant association was found only between TNBC and non-TNBC tumor size (pT) 
(p = 0.0011). Furthermore in TNBC more commonly than in non-TNBC the presence of necrosis 
in the tumor mass was observed (36%; 19.6%) and statistically significant correlation between 
TNBC and non-TNBC in the presence of necrosis was demonstrated (p = 0.036) (Table 1).
In all examined breast cancers we also assessed the expression of HIF-1α but not statistically sig-
nificant relationship between TNBC and non-TNBC was revealed. TNBC more often presented 
HIF-1α expression (43.2%) than non-TNBC (35.2%). In both groups we investigated correlation 
between the HIF-1α expression and features such as: tumor size (pT), histological grade (G1–
G3) and the presence of lymph node metastasis (pN1–pN3). While TNBC subgroup demon-
strated significant correlation between HIF-1α expression and tumor size (pT1–pT4) (p = 0.021). 
Detailed data and relationships between different parameters are presented in Tables 2 and 3.
Immunohistochemistry Frequency
n = 162
Prognostic parameters
Tumor necrosis Histological type of invasive 
breast cancer
positive negative p-value IDC-NST other 
types
p-value
TNBC 111
(100%)
40
(36.0)
71
(64.0)
0.036* 99
(89.1)
12 
(10.9)
0.858
non-TNBC 51
(100%)
10
(19.6)
41
(80.4)
45
(88.2)
6 (11.8)
Table 1. Relationship between immunohistochemical profile (TNBC/non-TNBC) and prognostic parameters invasive 
breast cancer with metastasis to lymph bodes (*statistically significant results p < 0.05).
Immunohistochemistry – basal panel for diagnosis of breast 
cancer
Frequency
n = 162
HIF-1α expression
Negative
(<10%)
Positive
(>10%)
p-value
TNBC (ER-/PR-/HER2-) 111
(100%)
63
(56.8)
48
(43.2)
0.339
non-TNBC (ER+/PR+/HER2+) 51
(100%)
33
(64.8)
18
(35.2)
Table 2. Relationship between basic immunohistochemical profile (ER, PR, HER2) and expression HIF-1α in invasive 
breast cancer with metastasis to lymph nodes (*statistically significant result p < 0.05).
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10. Discussion
A group of patients without the expression of any of the receptors qualifying for hormone 
therapy or targeted therapy against HER2 constitutes an important clinical problem in breast 
cancer treatment. Therefore, it seems important to undertake studies aimed at determining 
histopathological and immunohistochemical characteristics of this invasive group of triple-
negative breast cancer (TNBC). Triple-negative breast cancer is most commonly found in 
patients less than 50 years of age [49, 50]. Our study also found that TNBC is most common 
among women before 50 years of age (mean age 47.8).
In our study, histopathological subtyping of 111 patients with identified TNBC yielded the 
following results: 89.1% of IDC-NST and 10.9% of other special types of cancers. Infiltrating 
ductal carcinoma of no special type (IDC-NST) was the predominant histopathological type. 
Similar results were obtained by other researchers, e.g., Nofech-Mozes et al. [51], Williams 
et al. [52], Atik et al. [53], Rao et al. [54], Osman et al. [55], Sood et al. [56] and Tawfik et al. [57] 
(92%, 91%, 27%, 88%, 85.7%, 80.56% and 81.9%), who found that IDC-NST is the dominant 
histological type in a group of triple-negative breast cancers. Given the histological grade of 
malignancy, the largest group of triple-negative breast cancers encompassed tumors given G2 
and G3 grade. Statistical analysis showed no significant correlation between histological grade 
(G1–G3) and triple-negative tumor morphology (p > 0.05). The following authors obtained 
similar results: Atik et al. [53] assessing 75% of cancers in TNBC group as G3, Carey et al. [58], 
who found that in the TNBC group most cases are G3 cancers (26%). In a study on 16 cases 
Clinicopathological features of TNBC HIF-1 α expression
Negative
(<10%)
Positive
(>10%)
p-value
Histological grade G1 0 3 0.134
G2 35 23
G3 28 22
Tumor stage pT1 16 22 0.021*
pT2 46 23
pT3 1 2
pT4 0 1
Nodal stage pN1 30 20 0.821
pN2 25 21
pN3 8 7
Table 3. Clinicopathological features of TNBC and their relationship to expression of novel breast cancer marker - 
HIF-1α (*statistically significant result p < 0.05).
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of TNBC, Dabbs et al. [59] found that all tested tumors showed high degree of histological 
malignancy. Choi et al. [60] obtained similar results, stating that in a group of triple-negative 
cancers 63.1% were G3 tumors. Research by Zhou et al. [61] also showed that triple-negative 
G2 (51.6%) and G3 (45.2%) cancers were most numerous. Osman et al. [55] confirmed in their 
study that G3 carcinomas (61.9%) comprised the largest group of triple-negative tumors, while 
Sood et al. [56] pointed to G2 (47.22%) and G3 (38.89%) as most common tumors.
There are conflicting reports on the prevalence of lymph node metastases at the time of 
diagnosis among patients with TNBC. In our study we found that women without metasta-
ses to regional lymph nodes (pN0) comprised the largest group of all investigated patients 
with invasive triple-negative breast cancer (56.7%); no statistically significant relationship 
between lymph node status and histological type of TNBC-IC (p > 0.05) was noted. Lymph 
node status among patients with TNBC was reported as follows: 19.81%—N1, 19.81%—
N2, 3.6%—N3. The study also showed no association between tumor size and presence of 
lymph node metastasis in patients with TNBC, which stood in contradiction to the find-
ings of Thike et al. [62] who had demonstrated a relationship between tumor size and pres-
ence of nodal metastases. In studies by Rao et al. [54] lymph node metastases were found 
in 37 of 50 patients with TNBC (74% of cases), and TNBC was associated with higher rates 
of node-positive cases, which was in agreement with the findings of Carey Rakha et al. [58] 
and Rakha et al. [63].
In our study 30.9% of all tumors showed central necrosis. In TNBC more commonly than 
in non-TNBC the presence of necrosis was observed (36%; 19.6%). Yehia et al. [64] in their 
study divided breast cancers into three subgroups (TNBC, HER2+ and ER+/PR+). 15.3% of all 
tumors showed central fibrosis and tumor necrosis, which differed significantly among the 
three groups (p = 0.019). TNBC had the highest values among all groups even after adjust-
ing the results for age. Respectively necrosis was observed in 25.8% TNBC, 9.4% HER2+ and 
10.9% ER+/PR+ of cancers [64]. 62 TNBC, 64 HER2+, and 64 hormone-receptors positive breast 
cancers were evaluated also for HIF-1α expression. HIF-1α was expressed in 35.5% TNBC, 
45.3% HER2+ and 25.0% ER+/PR+ (p = 0.055). In our study HIF-1α expression was observed in 
43.2% TNBC and 35.3% non-TNBC.
Due to the fact that TNBC subtype frequently show morphologic evidence of hypoxia (central 
fibrosis and necrosis) [40, 41] an augmented expression of HIF-1α in tumors with a triple- 
negative phenotype was anticipated. In fact, this had been elegantly demonstrated through 
the preferential expression of HIF-1α in peri-necrotic tumor cells in TNBC and BRCA1 
mutated breast cancers [42].
HIF-1α overexpression is an indicator of poor prognosis and significant survival time reduc-
tion in patients suffering from breast cancer [45]. HIF-1 upregulates transcription of angio-
genic genes like EPO and vascular endothelial growth factor (VEGF), which induce sprouting 
of new vessels and in result they increase the risk of metastasis because they boost surface 
of contact between tumor cells and vasculature. HIF-1 induces transcription of cytoprotec-
tive proteins in malignant cells in hypoxic conditions. HIF-1α predicts poor prognosis breast 
cancer [46, 47].
Triple-Negative Breast Cancer: Expression of Hypoxia-Inducible Factor 1α in Triple-Negative…
http://dx.doi.org/10.5772/intechopen.75354
93
11. Conclusions
Demonstration of statistically significant relationship between HIF-1 α expression and tumor 
size (pT) in patients diagnosed with triple-negative breast cancer with lymph node metasta-
ses, may suggest that HIF-1 α expression in this group of patients may be an additional and 
significant marker in the evaluation of advance of the disease, affecting therapeutic decisions.
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